Press Room

Press Clipping / Jan 04, 2023

Hovione and GEA aim to increase adoption of continuous tableting

Outsourcing-Pharma, 4 January 2023

 

The two companies, who had previously established a customer-supplier relationship, have created an agreement to advance the technology and to encourage adoption.

Hovione and GEA will work together on continuous tableting technology, pairing the former's development and manufacturing expertise with the latter's engineering capabilities.

In terms of their respective capacities, Hovione is a contract development and manufacturing organization (CDMO) providing services for drug substance and drug product. GEA is a supplier for systems and components for the pharmaceutical industry, as well as the food and beverage industry.

The aim of the partnership is to accelerate the adoption of continuous tableting technology, and also to contribute to the establishment of new standards and market acceptance of the technology, the two companies stated.

In looking to promote continuous processes, the companies outlined that such systems allow for leaner and risk-reduced development paths, streamlined supply chains, increased built-in quality, and that the manufacturing processes themselves have greater flexibility and reduced complexity.

Both companies have been working in the continuous manufacturing space for a number of years. Nearly a decade ago, GEA began working with the US Food and Drug Administration (FDA) to validate continuous manufacturing, with the company stating at the time that the arrangement marked the "start of the end of batch manufacturing".

For Hovione, the company stated that it has been actively working on developing continuous tableting solutions for the last seven years, and it recently invested in the technology within its own manufacturing network.

In September 2022, Hovione announced that it had opened a new continuous manufacturing line at its Loures site, in Portugal. At the same time as the new line, the company established a multi-disciplinary global team specialized in continuous tableting.

On its latest move in the continuous tableting space, Hovione's CEO, Jean-Luc Herbeaux, stated, "Hovione has a track record in industrializing and democratizing emerging pharmaceutical technologies, such as amorphous solid dispersions by spray drying, and turn them into dependable and scalable offerings that are available to all... This collaboration with GEA, gives us the opportunity to link up with a leading designer and supplier of continuous tableting equipment solutions and bring continuous tableting to the next levels of reliability, flexibility and adoption".

In a recent interview with Outsourcing-Pharma, Bikash Chatterjee, CEO of Pharmatech Associates, stated that there is a growing momentum behind the switch to continuous manufacturing, even though this has been spoken of for a number of years.

Chatterjee noted that one aspect that could accelerate this shift is the national policy in the US to increase the manufacturing of certain pharmaceuticals on home soil. As a result, more efficient manufacturing, such as continuous, will be required to make the process commercially viable.

 

Read the entire article at Outsourcing-Pharma.com

 

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025